UPDATE 1-Atrium Innovations Q3 misses on higher forex loss

* Q3 EPS $0.39 vs est $0.40

* Q3 revenue $88.9 mln vs est $90.3 mln

* Sees sales momentum ramp up in Germany

Nov 10 (BestGrowthStock) – Dietary supplement-maker Atrium
Innovations’ (ATB.TO: ) third-quarter results missed estimates,
hurt by a rise in foreign exchange loss.

Third-quarter income fell 2 percent to $12.8 million, or 39
cents a share, from $13.1 million, or 40 cents a share, a year
ago.

The health products maker, whose key markets are in North
America and Europe, posted a 9 percent increase in revenue at
$88.9 million, helped by robust sales in Germany.

“In the early part of the fourth quarter, we are satisfied
with the continued sales momentum of our family of Wobenzym
products in Germany and worldwide,” said CEO Pierre Fitzgibbon,
in a statement.

Analysts on average expected the company to earn 40 cents
on revenue of $90.3 million, according to Thomson Reuters
I/B/E/S.

Foreign exchange loss was $297,000 as a result of the
negative impact of euro/U.S. dollar exchange rate, compared
with a loss of $127,000 a year ago.

Shares of the company have gained about 3 percent in value
since a Quebec-based financial holding firm sold 4 percent
stake in Atrium on Nov 3.

They closed at C$15.33 on Wednesday on the Toronto Stock
Exchange.
(Reporting by Gowri Jayakumar in Bangalore; Editing by Prem
Udayabhanu)

UPDATE 1-Atrium Innovations Q3 misses on higher forex loss